EUVIMEDEUVIMED entdecken
Crossref

Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer

L Philipps, N Porta, N James, R Huddart, S Hafeez, L Ballas, E Hall

Clinical Oncology · 2023-05 · 35 (5) · e336-e343

DOI: 10.1016/j.clon.2023.02.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Oncology, 2023-05. Verfasst von L Philipps und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Cancer Research, London, UK. Electronic address: Lara.philipps@icr.ac.uk. Hauptthemen laut MEDLINE: Radiation Injuries, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: BC2001, a randomised trial of treatment for muscle-invasive bladder cancer, demonstrated no difference in health-related quality of life (HRQoL) or late toxicity between patients receiving radical radiotherapy with and without chemotherapy. This secondary analysis explored sex-based differences in HRQoL and toxicity. MATERIALS AND METHODS: Participants completed the Functional Assessment of Cancer Therapy Bladder (FACT-BL) HRQoL questionnaires at baseline, end of treatment, 6 months and annually until 5 years. Clinicians assessed toxicity with the Radiation Therapy Oncology Group (RTOG) and Late Effects in Normal Tissues Subjective, Objective and Management (LENT/SOM) scoring systems at the same timepoints. The impact of sex on patient-reported HRQoL was evaluated using multivariate analyses of change in FACT-BL subscores from baseline to the timepoints of interest. For clinician-reported toxicity, differences were compared by calculating the proportion of patients with grade 3-4 toxicities occurring over the follow-up period. RESULTS: For both males and females, all FACT-BL subscores had a reduction in HRQoL at the end of treatment. For males, the mean bladder cancer subscale (BLCS) score remained stable through to year 5. For females, there was a decline in BLCS from baseline at years 2 and 3 with a return to baseline at year 5. At year 3, females had a statistically significant and clinically meaningful worsening of mean BLCS score (-5.18; 95% confidence interval -8.37 to -1.99), which was not seen in males (0.24; -0.76 to 1.23). RTOG toxicity was more frequent in females than males (27% versus 16%, P = 0.027). CONCLUSION: Results suggest that female patients treated with radiotherapy ± chemotherapy for localised bladder cancer report worse treatment-related toxicity in post-treatment years 2 and 3 than males.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiation InjuriesUrinary Bladder NeoplasmsHumansMaleFemaleQuality of LifeRadiotherapy DosageUrinary Bladder

Stichwörter der Autor:innen

Bladder canceroncologyquality of liferadiotherapy toxicitysex

Autor:innen und Institutionen

  • The Institute of Cancer Research, London, UK. Electronic address: Lara.philipps@icr.ac.uk.
  • The Institute of Cancer Research, London, UK.
  • The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.
  • Cedars-Sinai Medical Center, Los Angeles, California, USA.

Förderung

  • Cancer Research UK

Zitieren

APA

Philipps, L., Porta, N., James, N., Huddart, R., Hafeez, S., Ballas, L., & Hall, E. (2023). Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer. Clinical Oncology, 35(5), e336-e343. https://doi.org/10.1016/j.clon.2023.02.005

Vancouver

Philipps L, Porta N, James N, Huddart R, Hafeez S, Ballas L, et al. Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer. Clinical Oncology. 2023;35(5):e336-e343. doi:10.1016/j.clon.2023.02.005

BibTeX
@article{Philipps2023,
  author = {Philipps, L and Porta, N and James, N and Huddart, R and Hafeez, S and Ballas, L and Hall, E},
  title = {Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer},
  journal = {Clinical Oncology},
  year = {2023},
  volume = {35},
  number = {5},
  pages = {e336--e343},
  doi = {10.1016/j.clon.2023.02.005}
}
Kostenlos starten →